Streamlining the path from lab to market with 3D bioprinting
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.